Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.52 |
| ▸ | XBP1 | P17861 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6076944 | 0.93 | KMT2A (0.52) | KMT2AMEN1HPGDLMNAHTT | |
| SCHEMBL25372638 | 0.89 | KMT2A (0.46) | KMT2AMEN1HPGDLMNAHTT | |
| SCHEMBL11581595 | 0.88 | MEN1 (0.50) | KMT2AMEN1HPGDLMNAHTT | |
| SCHEMBL25369810 | 0.87 | MEN1 (0.44) | KMT2AMEN1HPGDLMNAHTT | |
| SCHEMBL6094414 | 0.87 | KMT2A (0.62) | KMT2AMEN1HPGDLMNAHTT | |
| SCHEMBL25372549 | 0.86 | MMEL1 (0.49) | KMT2AMEN1HPGDLMNAHTT | |
| SCHEMBL11583174 | 0.85 | MAPT (0.55) | KMT2AMEN1HPGDLMNAHTT | |
| SCHEMBL25372223 | 0.84 | FADS1 (0.47) | KMT2AMEN1HPGDLMNAHTT | |
| SCHEMBL25372530 | 0.82 | HPGD (0.49) | KMT2AMEN1HPGDLMNAHTT | |
| SCHEMBL25371120 | 0.82 | MCL1 (0.45) | KMT2AMEN1HPGDLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1438298-B1 | PIPERAZINE DERIVATIVES WITH CCR1 RECEPTOR ANTAGONIST ACTIVITY | PFIZER PROD INC (US) | 2010-01-27 | — | — | EP | disclosed |
| US-7098212-B2 | Piperazine derivatives | BLUMBERG LAURA C | 2006-08-29 | — | — | US | disclosed |
| EP-1583533-A1 | USE OF PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1438298-A1 | PIPERAZINE DERIVATIVES WITH CCR1 RECEPTOR ANTAGONIST ACTIVITY | Pfizer Products Inc. (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040092529-A1 | Methods of using piperazine derivatives | PFIZER INC | 2004-05-13 | — | — | US | disclosed |
| WO-2004039376-A1 | USE OF PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| US-20040034034-A1 | Novel piperazine derivatives | BLUMBERG LAURA C (US) | 2004-02-19 | — | — | US | disclosed |
| WO-2003035627-A1 | PIPERAZINE DERIVATIVES WITH CCR1 RECEPTOR ANTAGONIST ACTIVITY | PFIZER PRODUCTS INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092529-A1 | Methods of using piperazine derivatives | CCR1, CCR3, CCR5 | KMT2A 4125/4885MEN1 4618/4885HPGD 1457/4885 |
| US-20040034034-A1 | Novel piperazine derivatives | CCR1, CCRL2, CCR5 | KMT2A 3932/4885MEN1 4737/4885HPGD 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.